Jagsonpal Pharmaceuticals Q1 FY27 earnings call

Jagsonpal Pharmaceuticals reported a strong start to FY27, with Q1 sales growing 9% year-on-year to ₹82 crores. This growth translated into a 21% increase in operating EBITDA to ₹19 crores, with margins expanding by 240 basis points to over 23%. Net profits also saw a significant rise of 22% to ₹13 crores, improving margins by 176 basis points to 16%. The company's performance outpaced the industry in Pharmarack data, growing 18.9% against an industry average of 11.6%.

A key milestone in Q1 FY27 was the acquisition of an 85% stake in Aequitas Healthcare for a consideration of ₹20.8 crores, valuing the enterprise at approximately ₹25 crores. This acquisition provides Jagsonpal with an immediate and meaningful entry into the fast-growing hospital segment, offering opportunities for hospital formulary access, cross-selling, and operating synergies. Management expects Aequitas to start contributing meaningfully from the second year onwards, targeting ₹10 crores EBITDA by year two post-integration from its FY26 revenue base of ₹53 crores, and aiming for ₹100 crores in revenue within two and a half years.

The company is deliberately shifting its portfolio away from high-volume, low-margin acute therapies towards higher-value, stickier semi-chronic, and specialty treatments. This strategy has significantly enhanced the quality and productivity of new launches, with average monthly sales run rates almost doubling for these new brands. Jagsonpal aims to achieve a growth rate of 1.5x the industry growth rate in the coming quarters^⏳, supported by its semi-urban push and highly trained field force.

Jagsonpal is rebalancing its marketing investments from product-centric to brand-centricity, moving towards a more focused scientific promotion model to enhance physician engagement and long-term brand building. Operational excellence initiatives, including redesigned training, effective briefing meetings, and aligned incentive structures, have led to improved engagement and retention among the sales team. A company-wide 'lean and green' productivity program was also rolled out, contributing to better EBITDA margins and a healthier P&L.

In line with its commitment to shareholder value, Jagsonpal completed a ₹40 crores share buyback during the quarter, which was subscribed 3.67 times and made at a premium of about 40% to the market price. The company has recouped almost 50% of this payout within the quarter, maintaining a healthy closing cash balance of ₹170 crores. Additionally, the board recommended a dividend of 200% for FY26, including a special dividend of 75%.

The company emphasized strong operating cash generation and disciplined working capital management, which has enabled it to convert a significant portion of earnings into cash. Between FY22 and FY26, EBITDA and PAT grew 2.5x, compounding at almost 25% annually, while free cash flows increased 8x. Management noted that working capital days significantly improved between FY22 and FY24, dropping from 59 days to 22 days, primarily due to inventory control and stringent collection cycles.